Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India
-
Published:2021-03-03
Issue:1
Volume:13
Page:
-
ISSN:1756-994X
-
Container-title:Genome Medicine
-
language:en
-
Short-container-title:Genome Med
Author:
Alvarez-Silva CamilaORCID, Kashani Alireza, Hansen Tue Haldor, Pinna Nishal Kumar, Anjana Ranjit Mohan, Dutta Anirban, Saxena Shruti, Støy Julie, Kampmann Ulla, Nielsen Trine, Jørgensen Torben, Gnanaprakash Visvanathan, Gnanavadivel Rameshkumar, Sukumaran Aswath, Rani Coimbatore Subramanian Shanthi, Færch Kristine, Radha Venkatesan, Balasubramanyam Muthuswamy, Nair Gopinath Balakrish, Das Bhabatosh, Vestergaard Henrik, Hansen Torben, Mande Sharmila Shekhar, Mohan Viswanathan, Arumugam Manimozhiyan, Pedersen Oluf
Abstract
Abstract
Background
Type 2 diabetes (T2D), a multifactorial disease influenced by host genetics and environmental factors, is the most common endocrine disease. Several studies have shown that the gut microbiota as a close-up environmental mediator influences host physiology including metabolism. The aim of the present study is to examine the compositional and functional potential of the gut microbiota across individuals from Denmark and South India with a focus on T2D. Many earlier studies have investigated the microbiome aspects of T2D, and it has also been anticipated that such microbial associations would be dependent on diet and ethnic origin. However, there has been no large scale trans-ethnic microbiome study earlier in this direction aimed at evaluating any “universal” microbiome signature of T2D.
Methods
16S ribosomal RNA gene amplicon sequencing was performed on stool samples from 279 Danish and 294 Indian study participants. Any differences between the gut microbiota of both populations were explored using diversity measures and negative binomial Wald tests. Study samples were stratified to discover global and country-specific microbial signatures for T2D and treatment with the anti-hyperglycemic drug, metformin. To identify taxonomical and functional signatures of the gut microbiota for T2D and metformin treatment, we used alpha and beta diversity measures and differential abundances analysis, comparing metformin-naive T2D patients, metformin-treated T2D patients, and normoglycemic individuals.
Results
Overall, the gut microbial communities of Danes and Indians are compositionally very different. By analyzing the combined study materials, we identify microbial taxonomic and functional signatures for T2D and metformin treatment. T2D patients have an increased relative abundance of two operational taxonomic units (OTUs) from the Lachnospiraceae family, and a decreased abundance of Subdoligranulum and Butyricicoccus. Studying each population per se, we identified T2D-related microbial changes at the taxonomic level within the Danish population only.
Alpha diversity indices show that there is no significant difference between normoglycemic individuals and metformin-naive T2D patients, whereas microbial richness is significantly decreased in metformin-treated T2D patients compared to metformin-naive T2D patients and normoglycemic individuals. Enrichment of two OTUs from Bacteroides and depletion of Faecalibacterium constitute a trans-ethnic signature of metformin treatment.
Conclusions
We demonstrate major compositional differences of the gut microbiota between Danish and South Indian individuals, some of which may relate to differences in ethnicity, lifestyle, and demography. By comparing metformin-naive T2D patients and normoglycemic individuals, we identify T2D-related microbiota changes in the Danish and Indian study samples. In the present trans-ethnic study, we confirm that metformin changes the taxonomic profile and functional potential of the gut microbiota.
Funder
Innovationsfonden Danish Diabetes Academy Department of Biotechnology , Ministry of Science and Technology Novo Nordisk Fonden
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine
Reference33 articles.
1. Cersosimo E, Triplitt C, Solis-Herrera C, Mandarino LJ, DeFronzo RA. Pathogenesis of type 2 diabetes mellitus: MDText.com, Inc.; 2000. http://www.ncbi.nlm.nih.gov/pubmed/25905339. Accessed 12 Mar 2019 2. Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471(3):307–22. https://doi.org/10.1042/BJ20150497. 3. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. https://doi.org/10.1038/nature11450. 4. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota. Nature. 2015;528(7581):262–6. https://doi.org/10.1038/nature15766.Disentangling. 5. Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–8. https://doi.org/10.1038/nm.4345.
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|